About this trial
The purpose of this study is to evaluate the effect of atorvastatin on brain vessel reactivity and with it on blood flow in people with mild cognitive impairment.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
MCI defined by Clinical Dementia Rating (CDR) of 0.5 or 1.0.
Memory, processing speed, executive function, language - cognitive scores > 1.5 standard deviations below age-education norms.
Not demented by history.
Not taking statins currently or in the last 6 months.
Disqualifiers
Taking a statin currently or have taken a statin in the last 6 months.
Contraindications to taking a statin.
Transplant patient taking cyclosporine.
Unable to undergo MRI procedures (such as having an implanted pacemaker or defibrillator or stimulator or having non MRI compatible metal).
Trial design
Single group
Treatments tested in this trial
Atorvastatin Oral Tablet
DrugAtorvastatin pill 40 mg to be taken every night
Treatment groups
Trial outcomes
Primary outcomes
Change of MRI whole brain cerebrovascular reactivity (wbCVR)
MRI based CVR is a newer technique that measures dilatory function of the microvessels which have been shown to be superior to measurement of Cerebral blood flow (CBF) and have also been shown to be low in participants with MCI.
Secondary outcomes
Change in plasma exosomes
Endothelial-derived exosomes (EDE) reflect the neurochemistry of cerebrovascular endothelial cells, while neuronal-enriched extracellular vesicles (nEV) are associated with brain white matter hyperintensities.
Change in cognitive function (global neurocognitive measure)
Assessed by Global neurocognitive measure.
Change in cognitive function (domain-specific neurocognitive measure)
Assessed by Domain-specific neurocognitive measure.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Johns Hopkins University
Lead sponsor
The Richman Family Precision Medicine Center of Excellence in Alzheimer Disease
Collaborator